Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer

Gynecologic Oncology · Published 2026-07-01 · DOI 10.1016/j.ygyno.2026.06.010

Free full text

Authors (33)

Mark S. Shahin, Domenica Lorusso, Floor J. Backes, Maria-Pilar Barretina-Ginesta, David M. O'Malley, Frédéric Forget, Bhavana Pothuri, Sakari Hietanen, Colleen C. McCormick, Sophie Abadie-Lacourtoisie, Roisin E. O'Cearbhaill, Florian Heitz, Richard G. Moore, Amnon Amit, Lyndsay J. Willmott, María-Jesús Rubio Pérez, Robert A. Burger, Andrés Redondo, Dana M. Chase, Ignacio Romero, Kathleen N. Moore, Ignace Vergote, Noelle Cloven, Charlotte A. Haslund, Whitney S. Graybill, Alice Bergamini, Dominique Berton, Elena I. Braicu, Jonathan T. Lim, Amanda K. Golembesky, Luda Shtessel, Bradley J. Monk, Antonio González-Martín

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Shahin, M., Lorusso, D., Backes, F., et al. (2026). Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer. Gynecologic Oncology. https://doi.org/10.1016/j.ygyno.2026.06.010

Related articles